Posted by Michael Wonder on 06 Mar 2019
Firm in NHS row over cystic fibrosis drug paid almost no UK tax
6 March 2019 - European division of Vertex made loss while paying large sum to profitable US owner.
A drug company that has been in dispute with the NHS for two years over the high price it wants for a cystic fibrosis medicine has paid virtually no UK corporation tax, the Guardian can reveal.
Vertex Pharmaceuticals (Europe), based in London and Oxford, had a turnover of £5.3bn in the five years to the end of 2017, largely from sales of its cystic fibrosis drugs Orkambi and Kalydeco.
